Cytokinetics, Incorporated (CYTK)
| Market Cap | 10.70B +155.0% |
| Revenue (ttm) | 67.67M -21.1% |
| Net Income | -894.00M |
| EPS | -7.18 |
| Shares Out | 139.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,240,717 |
| Open | 76.09 |
| Previous Close | 76.76 |
| Day's Range | 75.67 - 77.08 |
| 52-Week Range | 32.89 - 88.31 |
| Beta | 0.38 |
| Analysts | Buy |
| Price Target | 108.85 (+41.38%) |
| Earnings Date | Aug 6, 2026 |
About CYTK
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h... [Read more]
Financial Performance
In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price target is $108.85, which is an increase of 41.38% from the latest price.
News
Cytokinetics price target raised to $112 from $106 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Cytokinetics (CYTK) to $112 from $106 and keeps a Buy rating on the shares as part of a broader research…
Cytokinetics price target raised to $85 from $83 at BofA
BofA raised the firm’s price target on Cytokinetics (CYTK) to $85 from $83 and keeps a Neutral rating on the shares. The company’s Q2 print was positive, given solid Myqorzo…
Cytokinetics price target raised to $112 from $102 at Needham
Needham analyst Serge Belanger raised the firm’s price target on Cytokinetics (CYTK) to $112 from $102 and keeps a Buy rating on the shares. The firm cites increased Myqorzo estimates…
Cytokinetics price target lowered to $112 from $117 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Cytokinetics (CYTK) to $112 from $117 and keeps an Outperform rating on the shares.
Cytokinetics price target raised to $110 from $105 at Citizens
Citizens analyst Jason Butler raised the firm’s price target on Cytokinetics (CYTK) to $110 from $105 and keeps an Outperform rating on the shares. Cytokinetics reported a strong Q2 with…
Cytokinetics Earnings Call Transcript: Q2 2026
MYQORZO's U.S. and European launches drove strong commercial momentum, with over 1,500 patients dispensed in Q2 and >40% new-to-brand share. Positive phase III results for aficamten in nHCM support a Q4 sNDA submission, while a $760M public offering strengthened the balance sheet.
Cytokinetics Earnings release: Q2 2026
Cytokinetics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Cytokinetics Quarterly report: Q2 2026
Cytokinetics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Cytokinetics reports Q2 EPS ($1.50), consensus ($1.60)
Reports Q2 revenue $28.62M, consensus $17.46M. “Our second quarter results demonstrate commercial launch momentum for MYQORZO alongside continued excellence for our development pipeline, both hallmark...
Cytokinetics wins UK approval, NICE backing for heart disease drug
Britain's medicines regulator approved Cytokinetics' drug for a rare heart condition on Thursday, with the country's cost-effectiveness watchdog recommending it for NHS reimbursement, potentially rea...
Cytokinetics announces MHRA authorization for Myqorzo
Cytokinetics (CYTK) announced that the Medicines and Healthcare products Regulatory Agency has granted Myqorzo a marketing authorisation across the United Kingdom for the treatment of symptomatic obst...
Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
Authorisation from MRHA and Recommendation from NICE This announcement is intended for business and financial media and investors only SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- C...
Cytokinetics to Announce Second Quarter Results on August 6, 2026
SOUTH SAN FRANCISCO, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 2026 at 4:00...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,2...
Cytokinetics price target lowered to $117 from $119 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Cytokinetics (CYTK) to $117 from $119 and keeps an Outperform rating on the shares as part of a broader…
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Cytokinetics upgraded to Buy from Neutral at UBS
UBS analyst Ashwani Verma upgraded Cytokinetics (CYTK) to Buy from Neutral with a price target of $115, up from $69. Cytokinetics is well positioned for upside driven by strong Myqorzo…
Cytokinetics price target raised to $118 from $100 at Mizuho
Mizuho raised the firm’s price target on Cytokinetics (CYTK) to $118 from $100 and keeps an Outperform rating on the shares. The firm updated the company’s model following the Q1…
Cytokinetics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
MYQORZO's global launch is driving rapid market expansion, with strong early adoption and positive clinical data supporting label growth into non-obstructive HCM. Regulatory milestones are on track, and a robust pipeline and financial position underpin continued innovation and competitive leadership.
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytoki...
Cytokinetics Transcript: Jefferies Global Healthcare Conference 2026
Aficamten's robust clinical results in non-obstructive HCM have generated strong enthusiasm among clinicians, with significant improvements in patient outcomes and a growing market opportunity. Early commercial uptake is exceeding expectations, driven by expanded physician adoption and strategic rollout initiatives.
Cytokinetics launches Myqorzo in Germany
Cytokinetics (CYTK) announced the first commercial European launch of Myqorzo in Germany for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. “Bringing Myqorzo t...
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
European Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first comme...
Cytokinetics to Participate in June Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following in...
Cytokinetics Transcript: AGM 2026
The meeting approved all proposals, including director elections and compensation. 2025 saw the first FDA approval and commercial launch of MYQORZO, strong financial growth, and pipeline advances. Strategic plans focus on global expansion, new indications, and disciplined capital allocation.